Are there any changes to the company’s guidance on net loss or earnings per share for the full year?
Answer
Based on the information released in Ginkgo Bioworks’ second‑quarter 2025 financial results (the PR Newswire announcement dated August 7 2025), the company did not modify its full‑year guidance for either net loss or earnings per share (EPS).
The press release focuses on two main points:
- Restructuring update – Ginkgo reported that it has achieved the expanded cost‑savings targets it set out in its restructuring plan, which total roughly $250 million in annual savings.
- Quarterly performance – The announcement provides the Q2 operating results, cash‑flow information, and other operational highlights.
There is no mention of a revision—upward or downward—to the previously‑issued full‑year outlook for net loss or EPS. The company’s guidance for the remainder of 2025 therefore remains unchanged from what was previously communicated.
Key take‑aways
| Item | What the release says | Implication for guidance |
|---|---|---|
| Restructuring | $250 M cost‑savings target met | No impact on guidance disclosed |
| Net‑loss guidance | Not addressed or revised | Guidance unchanged |
| EPS guidance | Not addressed or revised | Guidance unchanged |
Conclusion:
Ginkgo Bioworks has not announced any adjustments to its full‑year net‑loss or earnings‑per‑share guidance in this Q2 2025 results update. Investors can therefore continue to rely on the prior guidance figures that were in place before this release.